Document is current
Any future updates will be listed below
-
Authors
Smith, Michael
Newton, Robert
Owens, Sherry
Gong, Xiaohua
Tian, Chuan
Maleski, Janet
Leopold, Lance
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02178722 at ClinicalTrials.govnct02327078 at ClinicalTrials.govDocuments that mention this clinical trial
28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies
https://doi.org/10.1136/jitc-2020-sitc2020.0028
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
nct01685255 at ClinicalTrials.govDocuments that mention this clinical trial
28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies
https://doi.org/10.1136/jitc-2020-sitc2020.0028
nct02752074 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies
https://doi.org/10.1136/jitc-2020-sitc2020.0028
nct03589651 at ClinicalTrials.govDocuments that mention this clinical trial
28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies
https://doi.org/10.1136/jitc-2020-sitc2020.0028
Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy
https://doi.org/10.1136/jitc-2021-002616
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8<sup>+</sup> and CD4<sup>+</sup> T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
https://doi.org/10.1136/jitc-2020-000605
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
https://doi.org/10.1136/jitc-2023-006755
Documents that mention this clinical trial
28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies
https://doi.org/10.1136/jitc-2020-sitc2020.0028
- License Information
